Suprachoroidal drug delivery

REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting

Retrieved on: 
Wednesday, January 10, 2024
Suprachoroidal drug delivery, ABBV, AAV, Hawaiian Eye, FACS, Diabetic retinopathy, AMD, Webcast, AbbVie, Phase, EST

ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the Phase II AAVIATE® trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) at Hawaiian Eye and Retina 2024 Meeting being held January 13-19, 2024 in Maui, HI.

Key Points: 
  • ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the Phase II AAVIATE® trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) at Hawaiian Eye and Retina 2024 Meeting being held January 13-19, 2024 in Maui, HI.
  • ABBV-RGX-314 is an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet AMD, diabetic retinopathy and other additional chronic retinal conditions.
  • Those who plan on participating are advised to join 15 minutes prior to the start time.
  • A replay of the webcast will also be available via the Company's investor website approximately two hours after the call's conclusion.

Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting

Retrieved on: 
Tuesday, November 7, 2023
TKI, Neoplasm, Patient, SCS, FDA, Cohort, Axitinib, I Am the Moon, AMD, AAO, Safety, Inflammation, Melanoma, Diabetic retinopathy, HIV disease progression rates, Pharming, OASIS, American Academy, Retina, Paratriathlon, Annual general meeting, Clearside, Eye, Suprachoroidal drug delivery, Visual acuity, Oxygen toxicity, Pharmaceutical industry

“The AAO meeting held over the past week was exceptionally positive for Clearside and our clinical development partners,” said, George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer.

Key Points: 
  • “The AAO meeting held over the past week was exceptionally positive for Clearside and our clinical development partners,” said, George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer.
  • Two of our partners, REGENXBIO and Aura Biosciences, presented new, positive Phase 2 safety and clinical efficacy data from their respective programs utilizing our SCS Microinjector.
  • The findings from the survey indicated that physicians found the XIPERE injection easy to learn, with patient outcomes consistent with clinical trial data.
  • Clearside’s medical meeting presentations can be accessed on the Company’s Publications and Presentations page.

Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Patient, Physician, AAO, Safety, Triamcinolone, OASIS, Melanoma, Surgeon, American Academy, American Academy of Ophthalmology, Annual general meeting, Clearside, Eye, Suprachoroidal drug delivery, Pharmaceutical industry

ALPHARETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple oral and poster presentations will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting taking place November 3 – 6, 2023 in San Francisco, CA.

Key Points: 
  • ALPHARETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple oral and poster presentations will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting taking place November 3 – 6, 2023 in San Francisco, CA.
  • AAO is the world's largest association of eye physicians and surgeons.
  • Presentations will be delivered by leading physicians on behalf of Clearside and the Company’s commercial and development partners:
    Title: Safety and Tolerability of Suprachoroidal CLS-AX (Axitinib Injectable Suspension) in nAMD Patients in a Phase 1/2A Study, OASIS
    Title: Experience With Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Physician Survey
    Title: A Phase 2 Trial of Belzupacap Sarotalocan, a Targeted Investigational Therapy for Choroidal Melanoma via Suprachoroidal Administration

Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Retrieved on: 
Thursday, April 27, 2023
Drug delivery, OASIS, ARVO, Association for Research in Vision and Ophthalmology, Suprachoroidal drug delivery, Macular degeneration, AMD, Pharming, Safety, Eye, Clearside, Publication, Persistent, Pathology, Integrin, Annual general meeting, Toxicology, Triamcinolone, Macular edema, Poster, Patient, Research, Visual acuity, Axitinib, The Association, Pharmacology, SCS, Vaccine, Pharmaceutical industry, Ophthalmology

“In the studies presented, SCS delivery of small molecule suspensions offered targeted, compartmentalized, and durable drug delivery to the chorioretina.

Key Points: 
  • “In the studies presented, SCS delivery of small molecule suspensions offered targeted, compartmentalized, and durable drug delivery to the chorioretina.
  • Integrins play a major role in diverse biologic as well as pathologic processes such as cell adhesion/migration, angiogenesis, and immune responsiveness.
  • In the study, SCS delivery of an integrin inhibitor was well tolerated and offered targeted, compartmentalized, and durable drug delivery to the chorioretina.
  • Clearside’s medical meeting presentations can be accessed on the Company’s Publications and Presentations page.

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023
OASIS, ARVO, Association for Research in Vision and Ophthalmology, Suprachoroidal drug delivery, AMD, Safety, Eye, Persistent, Annual general meeting, Triamcinolone, Patient, Research, The Association, Pharmaceutical industry, Ophthalmology

ALPHARETTA, Ga., April 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple poster presentations will be given on the Company’s suprachoroidal injection delivery platform at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting taking place April 23-27, 2023, in New Orleans, LA.

Key Points: 
  • ALPHARETTA, Ga., April 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple poster presentations will be given on the Company’s suprachoroidal injection delivery platform at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting taking place April 23-27, 2023, in New Orleans, LA.
  • Title: Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients with Persistent Activity Following Anti-VEGF Therapy (OASIS, NCT04626128; Extension Study NCT05131646)
    Title: Suprachoroidal delivery of CLS-301, a potent small molecule integrin antagonist, offers multimonth durability and high bioavailability in the chorioretina
    Title: Early Adoption of Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Physician Survey

Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

Retrieved on: 
Tuesday, July 26, 2022
Time, Eye, GLOBE, Axitinib, Injection, Blood, Retina, Sclera, SCS, U.S. Securities and Exchange Commission, SEC, AMD, Diabetic retinopathy, Severe cognitive impairment, Compliance, Private Securities Litigation Reform Act, Periodic Report of the United States of America to the United Nations Committee Against Torture, Safety, COVID-19, TKI, Choroid, VEGF, MBA, Squamous cell carcinoma, Patient, Nasdaq, Pharmacokinetics, Suprachoroidal drug delivery, Annual report, Google Images, Growth, Pharmaceutical industry, Medical imaging, Clearside

ALPHARETTA, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today completion of dosing in Cohorts 3 and 4 of OASIS, its Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).

Key Points: 
  • OASIS is a U.S.-based, multi-center, open-label, dose-escalation trial in wet AMD patients to assess the safety and tolerability of a single dose of CLS-AX administered by suprachoroidal injection.
  • There is also an ongoing extension study to follow patients in Cohorts 2, 3 and 4 for three months after their completion of OASIS.
  • We are grateful to all our investigators and patients whose time and commitment made this first-in-human, suprachoroidal tyrosine kinase inhibitor trial possible.
  • OASIS is an open-label, dose-escalation Phase 1/2a trial in wet AMD patients to assess the safety and tolerability of a single dose of CLS-AX administered by suprachoroidal injection via Clearsides SCS Microinjector.

Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting

Retrieved on: 
Wednesday, July 6, 2022
Suprachoroidal drug delivery, Canadian Securities Administrators, Patient, SCS, Canker, COVID-19, Hypersensitivity, Bausch & Lomb, Bacteria, Lens (anatomy), Floater, Uveitis, Degenerative disease, Pregnancy, Fetus, FDA, Dose, Triamcinolone, ASRS, Conjunctiva, Cataract, Nursing, Hypothalamic–pituitary hormone, Macular edema, NYSE, Cushing's syndrome, Cornea, Instagram, Twitter, Eye, LinkedIn, Administration, Duane syndrome, HPA, Virus, Chickenpox, News, Chalazion, Chemosis, U.S. Securities and Exchange Commission, History, Photophobia, Meibomian gland, Glaucoma, Fungus, Risk, Vaccinia, Cover My Eyes (Pain and Heaven), Visual acuity, Intraocular pressure, Facebook, Fear, Society, Photopsia, Hyperglycemia, Pharmaceutical industry, Silviculture, Vaccine, Telescopic sight

VAUGHAN, ON, July 6, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that five presentations highlighting data from the XIPERE® (triamcinolone acetonide injectable suspension) pivotal Phase 3 program will be presented at the American Society of Retina Specialists (ASRS) 40th annual scientific meeting, which will take place in New York from July 13-16, 2022. The presentations will include a new post-hoc analysis of the pivotal Phase 3 trial (PEACHTREE) evaluating outcomes following treatment with XIPERE® in patients with macular edema associated with chronic uveitis.

Key Points: 
  • "At this year's ASRS annual meeting, we look forward to sharing these data with retina specialists on XIPERE, which we launched commercially in March," said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb.
  • Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with uveitis: Outcomes by anatomic subtypes in PEACHTREE.
  • Efficacy of suprachoroidal triamcinolone acetonide injectable suspension in the treatment of macular edema in patients with chronic uveitis.
  • XIPERE(triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 10, 2022
Bausch & Lomb, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Investor, Suprachoroidal drug delivery, Private Securities Litigation Reform Act, Therapeutic index, Conference call, Pharming, Retina, ET, Diabetic retinopathy, Safety, AMD, Uveitis, Company, Axitinib, GLOBE, Patient, Macular edema, SEC, Review, NASDAQ, Clinical trial, SCS, Choroid, Periodic Report of the United States of America to the United Nations Committee Against Torture, American Academy of Ophthalmology, Annual report, Conference, Acral lentiginous melanoma, U.S. Securities and Exchange Commission, Leadership, Sale, Eye, Income, Cohort, Webcast, Research, Technology, COVID-19, Toxic leukoencephalopathy, Angiogenesis, Food, Pharmaceutical industry, Video game, Animal, Clearside, Ophthalmology

ALPHARETTA, Ga., March 10, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., March 10, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.
  • Clearsides license and other revenue for the fourth quarter of 2021 was $25.7 million, compared to $11,000 for the fourth quarter of 2020.
  • Research and development expenses for the fourth quarter of 2021 were $3.8 million, compared to $4.5 million for the fourth quarter of 2020.
  • General and administrative expenses for the fourth quarter of 2021 were $3.1 million, compared to $2.6 million for the fourth quarter of 2020.

Clearside Biomedical Features FDA-Approved XIPERE™ in Multiple Presentations at the American Academy of Ophthalmology 2021 and American Uveitis Society Meetings

Retrieved on: 
Tuesday, November 16, 2021
American Academy of Ophthalmology, Suprachoroidal drug delivery, Clinical trial, Particle-size distribution, SCS, Safety, Clearside, Triamcinolone, Food, Acral lentiginous melanoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American Journal, Visual acuity, Macular edema, MBA, Rescue, Secretary General of the ASEAN, GLOBE, Patient, FDA, Choroid, Bausch & Lomb, BHC, NASDAQ, Eye, Diabetic retinopathy, Cataract, Sclera, American Academy, CST, AZALEA, JAMA Ophthalmology, Retina, Manuscript, Cohort, ASEAN countries in sporting events, Uveitis, AAO, MEDLINE, AMD, Incidence, Clinical, NYSE, Intravitreal injection, Physician, OCT, Animal, Pharmaceutical industry, Medical imaging

This study assessed these relationships, focusing on baseline anatomic features with potential prognostic value for visual response.

Key Points: 
  • This study assessed these relationships, focusing on baseline anatomic features with potential prognostic value for visual response.
  • This post hoc analysis of 198 eyes evaluated two Phase 3, 24-week UME clinical trials with CLS-TA (PEACHTREE and AZALEA).
  • A manuscript describing these results is in press at the American Journal of Ophthalmology, a peer-reviewed Medline-indexed journal.
  • Clearside American Uveitis Society Presentations:
    In conjunction with the AAO meeting, Clearside participated in the American Uveitis Society Fall Meeting on Sunday, November 14, 2021.

Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit

Retrieved on: 
Monday, April 5, 2021
Ophthalmology, Visual system, Vision, Sensory systems, Ophthalmic drug administration, Suprachoroidal drug delivery, Retina, Choroid, Eye disease

1:40 p.m.

Key Points: 
  • 1:40 p.m.
  • ET - Suprachoroidal Drug Delivery & CLS-AX: A Potential Solution for Treatment Burden
    2:55 p.m.
  • ET - Chair Led Q&A: Making Strides Forward in Drug Delivery & Dosing
    Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases.
  • Clearsides proprietary SCS Microinjector targeting the suprachoroidal space (SCS) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs.